FORBES-TATE

Lobbying for SANOFI U.S. · Multinational Pharmaceutical Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 19, 2026

Lobbying activity 3

Health Issues

Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines.

Medicare/Medicaid

Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers.

Taxation/Internal Revenue Code

Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.